Home » Newsletters » BioWorld Science

BioWorld Science

April 11, 2012

View Archived Issues

Preclinical and first clinical data disclosed on MLN-2480

Bayer Healthcare presents new oral selective PI3K inhibitor

Research at Astellas yields novel phosphodiesterase 9A inhibitors

UCB describes new PI3K inhibitors

Novel histone deacetylase inhibitors patented by Roche

IRM discloses new Trk inhibitors

Novel potential malaria therapies discovered

New HCV NS3/NS4A inhibitor characterized

Takeda reports on efforts to develop new HER2/EGFR kinase inhibitors

Mutant caveolin-1-derived peptide reduces atherosclerotic lesions

Novel ApoA-I-mimetic peptide shows promise as atherosclerosis drug

Affymax receives new milestone payment from Takeda for Omontys

AmiKet receives FDA fast track status

Phase II AKB-6548 study meets primary endpoint

Omeros begins enrollment in second phase III OMS-302 trial

Marshall Edwards clear to move lead mitochondrial inhibitor to clinic

PharmaMar to halt Irvalec development in gastroesophageal tumors

KineMed receives NIH grant to support development of ApoA-I HDL mimetic

Korlym now available in U.S.

Targacept reports revised topline data from phase II TC-6987 study

AnaptysBio enters strategic antibody discovery partnership

Sucampo reports topline phase III lubiprostone data

HSP 90 inhibitor enters phase I trial in multiple myeloma

Stealth Peptides reports on phase I Bendavia studies

Biovest to file marketing application in Canada

Amgen announces new acquisition agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 17, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...